HR 2610 RS
‘‘(2) COMPENSATION.—
‘‘(A) BONUS
PAYMENTS.—Notwithstanding
any other provision of law, the Director may
provide periodic bonus payments to any em-
ployee detailed to the Office of National Drug
Control Policy.
‘‘(B) RESTRICTIONS.—An amount paid
under this paragraph to an employee for any pe-
riod—
‘‘(i) shall not be greater than 20 per-
cent of the basic pay paid or payable to
such employee for such period; and
‘‘(ii) shall be in addition to the basic
pay of such employee.
‘‘(C) AGGREGATE AMOUNT.—The aggregate
amount paid during any fiscal year to an em-
ployee detailed to the Office of National Drug
Control Policy as basic pay, awards, bonuses,
and other compensation shall not exceed the an-
nual rate payable at the end of such fiscal year
for positions at level III of the Executive Sched-
ule.’’.
(d) COORDINATION WITH EXECUTIVE BRANCH DE-
PARTMENTS AND AGENCIES.—Section 1004 of the National
HR 2610 RS
Narcotics Leadership Act of 1988 (21 U.S.C. 1503) is
amended—
(1) by striking the section designation and the
section heading and inserting the following:
‘‘SEC. 1004. COORDINATION WITH NATIONAL DRUG CON-
TROL PROGRAM AGENCIES IN DEMAND RE-
DUCTION, SUPPLY REDUCTION, AND STATE
AND LOCAL AFFAIRS.’’;
(2) in subsection (a)—
(A) by striking paragraph (1) and inserting
the following:
‘‘(1) IN GENERAL.—Upon the request of the Di-
rector, the head of any National Drug Control Pro-
gram agency shall cooperate with and provide to the
Director any statistics, studies, reports, and other in-
formation of the agency pertaining to—
‘‘(A) drug abuse control; or
‘‘(B) the manner in which amounts made
available to that agency for drug control are
being used by that agency.’’; and
(B) by adding at the end the following:
‘‘(3) ILLEGAL
DRUG
CULTIVATION.—The Sec-
retary of Agriculture shall annually submit to the Di-
rector an assessment of the acreage of illegal drug cul-
tivation in the United States.’’.
HR 2610 RS
(e) DEVELOPMENT
AND SUBMISSION
OF NATIONAL
DRUG CONTROL STRATEGY.—Section 1005 of the National
Narcotics Leadership Act of 1988 (21 U.S.C. 1504) is
amended to read as follows:
‘‘SEC. 1005. DEVELOPMENT, SUBMISSION, IMPLEMENTA-
TION, AND ASSESSMENT OF NATIONAL DRUG
CONTROL STRATEGY.
‘‘(a) TIMING, CONTENTS, AND PROCESS FOR DEVELOP-
MENT
AND SUBMISSION
OF NATIONAL DRUG CONTROL
STRATEGY.—
‘‘(1) TIMING.—Not later than February 1, 1997,
the President shall submit to Congress a National
Drug Control Strategy, which shall set forth a com-
prehensive plan, covering a period of not more than
10 years, for reducing drug abuse and the con-
sequences of drug abuse in the United States, by lim-
iting the availability of and reducing the demand for
illegal drugs.
‘‘(2) CONTENTS.—
‘‘(A) IN
GENERAL.—The National Drug
Control Strategy submitted under paragraph (1)
shall include—
‘‘(i) 
comprehensive, 
research-based,
long-range, quantifiable, goals for reducing
HR 2610 RS
drug abuse and the consequences of drug
abuse in the United States;
‘‘(ii) short-term measurable objectives
to accomplish long-term quantifiable goals
that the Director determines may be real-
istically achieved during the 2-year period
beginning on the date on which the strategy
is submitted;
‘‘(iii) 5-year projections for program
and budget priorities; and
‘‘(iv) a review of State, local, and pri-
vate sector drug control activities to ensure
that the United States pursues well-coordi-
nated and effective drug control at all levels
of government.
‘‘(B) CLASSIFIED INFORMATION.—Any con-
tents of the National Drug Control Strategy that
involves information properly classified under
criteria established by an Executive order shall
be presented to Congress separately from the rest
of the Strategy.
‘‘(3) PROCESS FOR DEVELOPMENT AND SUBMIS-
SION.—
HR 2610 RS
‘‘(A) CONSULTATION.—In developing and
effectively implementing the National Drug Con-
trol Strategy, the Director—
‘‘(i) shall consult with—
‘‘(I) the heads of the National
Drug Control Program agencies;
‘‘(II) Congress;
‘‘(III) State and local officials;
‘‘(IV) private citizens and organi-
zations with experience and expertise
in demand reduction; and
‘‘(V) private citizens and organi-
zations with experience and expertise
in supply reduction; and
‘‘(ii) may require the National Drug
Intelligence Center and the El Paso Intel-
ligence Center to undertake specific tasks or
projects to implement the Strategy.
‘‘(B) INCLUSION
IN
STRATEGY.—The Na-
tional Drug Control Strategy under this sub-
section, and each report submitted under sub-
section (b), shall include a list of each entity
consulted under subparagraph (A)(i).
‘‘(4) MODIFICATION
AND
RESUBMITTAL.—Not-
withstanding any other provision of law, the Director
HR 2610 RS
may modify a National Drug Control Strategy sub-
mitted under paragraph (1) at any time.
‘‘(b) ANNUAL STRATEGY REPORT.—
‘‘(1) IN GENERAL.—Not later than February 1,
1998, and on February 1 of each year thereafter, the
President shall submit to Congress a report on the
progress in implementing the Strategy under sub-
section (a), which shall include—
‘‘(A) an assessment of the Federal effective-
ness in achieving the Strategy goals and objec-
tives using the performance measurement system
described in subsection (c), including—
‘‘(i) an assessment of drug use and
availability in the United States; and
‘‘(ii) an estimate of the effectiveness of
interdiction, treatment, prevention, law en-
forcement, 
and 
international 
programs
under the National Drug Control Strategy
in effect during the preceding year, or in ef-
fect as of the date on which the report is
submitted;
‘‘(B) any modifications of the Strategy or
the performance measurement system described
in subsection (c);
HR 2610 RS
‘‘(C) an assessment of how the budget pro-
posal submitted under section 1003(c) is in-
tended to implement the Strategy and whether
the funding levels contained in such proposal are
sufficient to implement such Strategy;
‘‘(D) beginning on February 1, 1999, and
every 2 years thereafter, measurable data evalu-
ating the success or failure in achieving the
short-term measurable objectives described in
subsection (a)(2)(A)(ii);
‘‘(E) an assessment of current drug use (in-
cluding inhalants) and availability, impact of
drug use, and treatment availability, which as-
sessment shall include—
‘‘(i) estimates of drug prevalence and
frequency of use as measured by national,
State, and local surveys of illicit drug use
and by other special studies of—
‘‘(I) casual and chronic drug use;
‘‘(II) high-risk populations, in-
cluding school dropouts, the homeless
and transient, arrestees, parolees, pro-
bationers, and juvenile delinquents;
and
HR 2610 RS
‘‘(III) drug use in the workplace
and the productivity lost by such use;
‘‘(ii) an assessment of the reduction of
drug availability against an ascertained
baseline, as measured by—
‘‘(I) the quantities of cocaine, her-
oin, 
marijuana, 
methamphetamine,
and other drugs available for consump-
tion in the United States;
‘‘(II) the amount of marijuana,
cocaine, and heroin entering the Unit-
ed States;
‘‘(III) the number of hectares of
marijuana, poppy, and coca cultivated
and destroyed;
‘‘(IV) the number of metric tons of
marijuana, heroin, and cocaine seized;
‘‘(V) the number of cocaine and
methamphetamine processing labora-
tories destroyed;
‘‘(VI) changes in the price and
purity of heroin and cocaine;
‘‘(VII) the amount and type of
controlled substances diverted from le-
HR 2610 RS
gitimate retail and wholesale sources;
and
‘‘(VIII) the effectiveness of Federal
technology programs at improving
drug detection capabilities in interdic-
tion, and at United States ports of
entry;
‘‘(iii) an assessment of the reduction of
the consequences of drug use and availabil-
ity, which shall include estimation of—
‘‘(I) the burden drug users placed
on hospital emergency departments in
the United States, such as the quantity
of drug-related services provided;
‘‘(II) the annual national health
care costs of drug use, including costs
associated with people becoming in-
fected 
with 
the 
human 
immuno-
deficiency virus and other infectious
diseases as a result of drug use;
‘‘(III) the extent of drug-related
crime and criminal activity; and
‘‘(IV) the contribution of drugs to
the underground economy, as measured
HR 2610 RS
‘‘(F) an assessment of private sector initia-
tives and cooperative efforts between the Federal
Government and State and local governments for
drug control.
‘‘(2) SUBMISSION OF REVISED STRATEGY.—The
President may submit to Congress a revised National
Drug Control Strategy that meets the requirements of
this section—
‘‘(A) at any time, upon a determination by
the President and the Director that the National
Drug Control Strategy in effect is not suffi-
ciently effective; and
‘‘(B) if a new President or Director takes
office.
‘‘(c) PERFORMANCE MEASUREMENT SYSTEM.—
‘‘(1) IN GENERAL.—Not later than November 1,
1997, the Director shall submit to Congress a descrip-
tion of the national drug control performance meas-
urement system, designed in consultation with af-
fected National Drug Control Program agencies,
that—
‘‘(A) develops performance objectives, meas-
ures, and targets for each National Drug Control
Strategy goal and objective;
HR 2610 RS
‘‘(B) revises performance objectives, meas-
ures, and targets, to conform with National Drug
Control Program Agency budgets;
‘‘(C) identifies major programs and activi-
ties of the National Drug Control Program agen-
cies that support the goals and objectives of the
National Drug Control Strategy;
‘‘(D) evaluates implementation of major
program activities supporting the National Drug
Control Strategy developed under section 1005;
‘‘(E) monitors consistency between the drug-
related goals and objectives of the National Drug
Control Program agencies and ensures that drug
control agency goals and budgets support and
are fully consistent with the National Drug Con-
trol Strategy; and
‘‘(F) coordinates the development and im-
plementation of national drug control data col-
lection and reporting systems to support policy
formulation and performance measurement, in-
cluding an assessment of—
‘‘(i) the quality of current drug use
measurement instruments and techniques to
measure supply reduction and demand re-
duction activities;
HR 2610 RS
‘‘(ii) the adequacy of the coverage of
existing national drug use measurement in-
struments and techniques to measure the
casual drug user population and groups
that are at risk for drug use; and
‘‘(iii) the actions the Director shall
take to correct any deficiencies and limita-
tions identified pursuant to subparagraphs
(A) and (B) of subsection (b)(4).
‘‘(2) MODIFICATIONS.—A description of any
modifications made during the preceding year to the
national drug control performance measurement sys-
tem described in paragraph (1) shall be included in
each report submitted under subsection (b).’’.
(f) HIGH INTENSITY DRUG TRAFFICKING AREAS PRO-
GRAM.—The National Narcotics Leadership Act of 1988 (21
U.S.C. 1501 et seq.) is amended by inserting after section
1005 the following:
‘‘SEC. 1005A. HIGH INTENSITY DRUG TRAFFICKING AREAS
PROGRAM.
‘‘(a) ESTABLISHMENT.—There is established in the Of-
fice a program to be known as the High Intensity Drug
Trafficking Areas Program.
‘‘(b) DESIGNATION.—The Director, upon consultation
with the Attorney General, the Secretary of the Treasury,
HR 2610 RS
heads of the National Drug Control Program agencies, and
the Governor of each State, may designate any specified
area of the United States as a high intensity drug traffick-
ing area. After making such a designation and in order
to provide Federal assistance to the area so designated, the
Director may—
‘‘(1) obligate such sums as appropriated for the
High Intensity Drug Trafficking Areas Program;
‘‘(2) direct the temporary reassignment of Fed-
eral personnel to such area, subject to the approval of
the Secretary of the department or head of the agency
that employs such personnel;
‘‘(3) take any other action authorized under sec-
tion 1003 to provide increased Federal assistance to
such areas;
‘‘(4) coordinate activities under this paragraph
(specifically administrative, recordkeeping, and funds
management activities) with State and local officials.
‘‘(c) FACTORS FOR CONSIDERATION.—In considering
whether to designate an area under this section as a high
intensity drug trafficking area, the Director shall consider,
in addition to such other criteria as the Director considers
to be appropriate, the extent to which—
‘‘(1) the area is a center of illegal drug produc-
tion, manufacturing, importation, or distribution;
HR 2610 RS
‘‘(2) State and local law enforcement agencies
have committed resources to respond to the drug traf-
ficking problem in the area, thereby indicating a de-
termination to respond aggressively to the problem;
‘‘(3) drug-related activities in the area are hav-
ing a harmful impact in other areas of the country;
and
‘‘(4) a significant increase in allocation of Fed-
eral resources is necessary to respond adequately to
drug-related activities in the area.’’.
(g) COUNTER-DRUG TECHNOLOGY ASSESSMENT CEN-
TER.—Section 1008 of the National Narcotics Leadership
Act of 1988 (21 U.S.C. 1505) is amended to read as follows:
‘‘SEC. 1008. COUNTER-DRUG TECHNOLOGY ASSESSMENT
CENTER.
‘‘(a) ESTABLISHMENT.—There is established within
the Office the Counter-Drug Technology Assessment Center
(in this section referred to as the ‘Center’). The Center shall
operate under the authority of the Director of National
Drug Control Policy and shall serve as the central counter-
drug technology research and development organization of
the United States Government.
‘‘(b) DIRECTOR OF TECHNOLOGY.—There shall be at
the head of the Center the Director of Technology, who shall
be appointed by the Director of National Drug Control Pol-
HR 2610 RS
icy from among individuals qualified and distinguished in
the area of science, medicine, engineering, or technology.
‘‘(c) ADDITIONAL RESPONSIBILITIES OF THE DIREC-
TOR OF NATIONAL DRUG CONTROL POLICY.—
‘‘(1) IN GENERAL.—The Director, acting through
the Director of Technology shall—
‘‘(A) identify and define the short-, me-
dium-, and long-term scientific and technological
needs of Federal, State, and local drug supply
reduction agencies, including—
‘‘(i) advanced surveillance, tracking,
and radar imaging;
‘‘(ii) electronic support measures;
‘‘(iii) communications;
‘‘(iv) data fusion, advanced computer
systems, and artificial intelligence; and
‘‘(v) chemical, biological, radiological
(including neutron, electron, and graviton),
and other means of detection;
‘‘(B) identify demand reduction basic and
applied research needs and initiatives, in con-
sultation with affected National Drug Control
Program agencies, including—
‘‘(i) 
improving 
treatment 
through
neuroscientific advances;
HR 2610 RS
‘‘(ii) improving the transfer of bio-
medical research to the clinical setting; and
‘‘(iii) in consultation with the Na-
tional Institute on Drug Abuse, and through
interagency agreements or grants, examin-
ing addiction and rehabilitation research
and the application of technology to ex-
panding the effectiveness or availability of
drug treatment;
‘‘(C) make a priority ranking of such needs
identified in subparagraphs (A) and (B) accord-
ing to fiscal and technological feasibility, as part
of a National Counter-Drug Enforcement Re-
search and Development Program;
‘‘(D) oversee and coordinate counter-drug
technology initiatives with related activities of
other Federal civilian and military departments;
‘‘(E) provide support to the development
and implementation of the national drug control
performance measurement system; and
‘‘(F) pursuant to the authority of the Direc-
tor of National Drug Control Policy under sec-
tion 1003, submit requests to Congress for the re-
programming or transfer of funds appropriated
HR 2610 RS
for counter-drug technology research and develop-
ment.
‘‘(2) LIMITATION ON AUTHORITY.—The authority
granted to the Director under this subsection shall not
extend to the award of contracts, management of indi-
vidual projects, or other operational activities.
‘‘(d) ASSISTANCE AND SUPPORT TO OFFICE OF NA-
TIONAL DRUG CONTROL POLICY.—The Department of De-
fense and the Department of Health and Human Services
shall, to the fullest extent possible, render assistance and
support to the Office and to the Director in the conduct
of counter-drug technology assessment.’’.
(h) TERMINATION OF OFFICE OF NATIONAL DRUG
CONTROL POLICY.—Section 1009 of the National Narcotics
Leadership Act of 1988 (42 U.S.C. 1506) is amended to
read as follows:
‘‘SEC. 1009. TERMINATION OF OFFICE OF NATIONAL DRUG
CONTROL POLICY.
‘‘Effective on September 30, 2001, this subtitle and the
amendments made by this subtitle are repealed.’’.
(i) COUNCIL ON COUNTER-NARCOTICS.—Section 1010
of the National Narcotics Leadership Act of 1988 (21 U.S.C.
1509) is amended to read as follows:
HR 2610 RS
‘‘SEC. 1010. COUNCIL ON COUNTER-NARCOTICS.
‘‘(a) ESTABLISHMENT.—There is established a council
to be known as the President’s Council on Counter-Narcotics
(in this section referred to as the ‘Council’).
‘‘(b) MEMBERSHIP.—
‘‘(1) IN GENERAL.—Subject to paragraph (2), the
Council shall be composed of 16 members, of whom—
‘‘(A) 1 shall be the President, who shall
serve as Chairman of the Council;
‘‘(B) 1 shall be the Vice President;
‘‘(C) 1 shall be the Secretary of State;
‘‘(D) 1 shall be the Secretary of the Treas-
ury;
‘‘(E) 1 shall be the Secretary of Defense;
‘‘(F) 1 shall be the Attorney General;
‘‘(G) 1 shall be the Secretary of Transpor-
tation;
‘‘(H) 1 shall be the Representative of the
United States of America to the United Nations;
‘‘(I) 1 shall be the Director of the Office of
Management and Budget;
‘‘(J) 1 shall be the Chief of Staff to the
President;
‘‘(K) 1 shall be the Director of the Office,
who shall serve as the Executive Director of the
Council;
HR 2610 RS
‘‘(L) 1 shall be the Director of Central Intel-
ligence;
‘‘(M) 1 shall be the Assistant to the Presi-
dent for National Security Affairs;
‘‘(N) 1 shall be the Counsel to the President;
‘‘(O) 1 shall be the Chairman of the Joint
Chiefs of Staff; and
‘‘(P) 1 shall be the National Security Ad-
viser to the Vice President.
‘‘(2) ADDITIONAL
MEMBERS.—The President
may, in the discretion of the President, appoint addi-
tional members to the Council, of whom—
‘‘(A) 1 may be the Secretary of Health and
Human Services;
‘‘(B) 1 may be the Secretary of Education;
‘‘(C) 1 may be the Assistant to the Presi-
dent for Domestic Policy; and
‘‘(D) 1 or more may be other officials of de-
partments and agencies of the Federal Govern-
ment, as determined by the President.
‘‘(c) MEETINGS OF THE COUNCIL.—The Council shall
meet not less than quarterly at the call of the President (or,
upon the direction of the President, at the call of the Vice
President). The President (or in the absence of the Presi-
HR 2610 RS
dent, the Vice President) shall preside over each meeting
of the Council.
‘‘(d) FUNCTIONS.—
‘‘(1) IN GENERAL.—The Council shall advise and
assist the President in—
‘‘(A) providing direction and oversight for
the national drug control strategy, including re-
lating drug control policy to other national secu-
rity interests and establishing priorities; and
‘‘(B) ensuring coordination among depart-
ments and agencies concerning implementation
of the President’s national drug control strategy.
‘‘(2) DUTIES
OF
DIRECTOR.—The Director
shall—
‘‘(A) be the senior drug control policy offi-
cial in the executive branch; and
‘‘(B) serve as the chief drug control policy
spokesman for the President.
‘‘(3) NATIONAL
SECURITY
MATTERS.—In any
matter affecting national security interests, the Direc-
tor shall work in conjunction with the Assistant to the
President for National Security Affairs.
‘‘(e) ADMINISTRATION.—
‘‘(1) IN GENERAL.—The Council may utilize es-
tablished or ad hoc committees, task forces, or inter-
HR 2610 RS
agency groups chaired by the Director (or a represent-
ative of the Director) in carrying out the functions of
the Council under this section.
‘‘(2) STAFF.—The staff of the Office, in coordi-
nation with the staffs of the Vice President and the
Assistant to the President for National Security Af-
fairs, shall act as staff for the Council.
‘‘(3) COOPERATION
FROM
OTHER
AGENCIES.—
Each department and agency of the executive branch
shall—
‘‘(A) cooperate with the Council in carrying
out the functions of the Council under this sec-
tion; and
‘‘(B) provide such assistance, information,
and advice as the Council may request, to the ex-
tent permitted by law.’’.
(j) PARENTS ADVISORY COUNCIL ON YOUTH DRUG
ABUSE.—The National Narcotics Leadership Act of 1988
(21 U.S.C. 1501 et seq.) is amended by inserting after sec-
tion 1010 the following:
‘‘SEC. 1010A. PARENTS ADVISORY COUNCIL ON YOUTH
DRUG ABUSE.
‘‘(a) ESTABLISHMENT.—
‘‘(1) ESTABLISHMENT.—There is established a
Council to be known as the Parents Advisory Council
HR 2610 RS
on Youth Drug Abuse (in this section referred to as
the ‘Council’).
‘‘(2) MEMBERSHIP.—
‘‘(A) COMPOSITION.—The Council shall be
composed of 16 members, of whom—
‘‘(i) 4 shall be appointed by the Presi-
dent, each of whom shall be a parent or
guardian of a child who is not less than 6
and not more than 18 years of age as of the
date on which the appointment is made;
‘‘(ii) 4 shall be appointed by the Ma-
jority Leader of the Senate, 3 of whom shall
be a parent or guardian of a child who is
not less than 6 and not more than 18 years
of age as of the date on which the appoint-
ment is made;
‘‘(iii) 2 shall be appointed by the Mi-
nority Leader of the Senate, each of whom
shall be a parent or guardian of a child
who is not less than 6 and not more than
18 years of age as of the date on which the
appointment is made;
‘‘(iv) 4 shall be appointed by the
Speaker of the House of Representatives, 3
of whom shall be a parent or guardian of
HR 2610 RS
a child who is not less than 6 and not more
than 18 years of age as of the date on which
the appointment is made; and
‘‘(v) 2 shall be appointed by the Minor-
ity Leader of the House of Representatives,
each of whom shall be a parent or guardian
of a child who is not less than 6 and not
more than 18 years of age as of the date on
which the appointment is made.
‘‘(B) REQUIREMENTS.—
‘‘(i) IN
GENERAL.—Each member of
the Council shall be an individual from the
private sector with a demonstrated interest
and expertise in research, education, treat-
ment, or prevention activities related to
youth drug abuse.
‘‘(ii) REPRESENTATIVES OF NONPROFIT
ORGANIZATIONS.—Not less than 1 member
appointed under each of clauses (i) through
(v) of paragraph (1)(A) shall be a rep-
resentative of a nonprofit organization fo-
cused on involving parents in antidrug edu-
cation and prevention.
‘‘(C) DATE.—The appointments of the ini-
tial members of the Council shall be made not
HR 2610 RS
later than 60 days after the date of enactment of
this section.
‘‘(D) DIRECTOR.—The Director may, in the
discretion of the Director, serve as an adviser to
the Council and attend such meetings and hear-
ings of the Council as the Director considers to
be appropriate.
‘‘(3) PERIOD OF APPOINTMENT; VACANCIES.—
‘‘(A) 
PERIOD
OF
APPOINTMENT.—Each
member of the Council shall be appointed for a
term of 3 years, except that, of the initial mem-
bers of the Council—
‘‘(i) 1 member appointed under each of
clauses (i) through (v) of paragraph (1)(A)
shall be appointed for a term of 1 year; and
‘‘(ii) 1 member appointed under each
of clauses (i) through (v) of paragraph
(1)(A) shall be appointed for a term of 2
years.
‘‘(B) VACANCIES.—Any vacancy in the
Council shall not affect its powers, provided that
a quorum is present, but shall be filled in the
same manner as the original appointment. Any
member appointed to fill a vacancy occurring be-
fore the expiration of the term for which the
HR 2610 RS
member’s predecessor was appointed shall be ap-
pointed only for the remainder of that term.
‘‘(C) APPOINTMENT OF SUCCESSOR.—To the
extent necessary to prevent a vacancy in the
membership of the Council, a member of the
Council may serve for not more than 6 months
after the expiration of the term of that member,
if the successor of that member has not been ap-
pointed.
‘‘(4) INITIAL MEETING.—Not later than 120 days
after the date on which all initial members of the
Council have been appointed, the Council shall hold
its first meeting.
‘‘(5) MEETINGS.—The Council shall meet at the
call of the Chairperson.
‘‘(6) QUORUM.—Nine members of the Council
shall constitute a quorum, but a lesser number of
members may hold hearings.
‘‘(7) CHAIRPERSON AND VICE CHAIRPERSON.—
‘‘(A) IN
GENERAL.—The members of the
Council shall select a Chairperson and Vice
Chairperson from among the members of the
Council.
‘‘(B) 
DUTIES
OF
CHAIRPERSON.—The
Chairperson of the Council shall—
HR 2610 RS
that would be required by Federal drug control agencies in
order to achieve a level of interdiction success at or above
the highest level achieved before the date of enactment of
this Act, not later than 90 days after the date of enactment
of this Act, the Director shall submit to Congress and to
each Federal drug control program agency a report, which
shall include—
(1) with respect to the southern and western bor-
der regions of the United States (including the Pacific
coast, the border with Mexico, the Gulf of Mexico
coast, and other ports of entry) and in overall totals,
data relating to—
(A) the amount of marijuana, heroin, meth-
amphetamine, and cocaine—
(i) seized during the year of highest re-
corded seizures for each drug in each region
and during the year of highest recorded
overall seizures; and
(ii) disrupted during the year of high-
est recorded disruptions for each drug in
each region and during the year of highest
recorded overall seizures; and
(B) the number of persons arrested for vio-
lations of section 1010(a) of the Controlled Sub-
stances Import and Export Act (21 U.S.C.